GlassScriptPhysician profile
Kathi E Reynolds
NPI 1972856789
$4,520.85
in general payments reported to CMS, 2019-2025
44 companies · $599 in 2025
The $599 reported for 2025 was more than what 76% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,005 · 2022: $496 · 2023: $1,251 · 2024: $1,169 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.12 |
| Education | $229.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $289.72 | 2022-2025 | Venclexta, Polivy, Tecentriq Hybreza |
| Amgen INC. | $288.43 | 2021-2023 | Lumakras |
| Incyte Corporation | $285.20 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $252.13 | 2023-2025 | |
| Daiichi Sankyo INC. | $251.99 | 2021-2025 | Enhertu |
| Gilead Sciences, INC. | $220.77 | 2023-2024 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $216.50 | 2021-2025 | |
| Abbvie INC. | $214.83 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $212.76 | 2022-2023 | Imbruvica |
| Janssen Biotech, INC. | $211.74 | 2022-2025 | Talvey, Tecvayli, Carvykti |
| Merck Sharp & Dohme LLC | $195.88 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $175.50 | 2023-2024 | Imfinzi, Calquence, Enhertu |
| Janssen Pharmaceuticals, INC | $155.22 | 2023-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $154.11 | 2021-2024 | Fruzaqla |
| Jazz Pharmaceuticals INC. | $136.66 | 2021-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $111.73 | 2021-2025 | Xtandi, Padcev |
| E.R. Squibb & Sons, L.L.C. | $111.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.20 | 2022-2024 | |
| Stemline Therapeutics INC. | $93.94 | 2023-2025 | Orserdu |
| Seagen INC. | $85.55 | 2022-2023 | Padcev, Tukysa |
| Aveo Pharmaceuticals, INC. | $78.20 | 2024-2025 | |
| Celgene Corporation | $78.13 | 2021-2023 | Reblozyl, Pomalyst |
| Pharmaessentia USA Corporation | $49.87 | 2023-2024 | Besremi |
| Lilly USA, LLC | $49.55 | 2021-2024 | Retevmo, Jaypirca, Verzenio |
| Genzyme Corporation | $44.70 | 2023-2025 | |
| Emd Serono, INC. | $42.45 | 2024 | |
| Sobi, INC | $36.13 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $35.67 | 2025 | Libtayo |
| Taiho Oncology, INC. | $31.88 | 2023 | |
| Array Biopharma INC | $30.58 | 2023-2024 | Braftovi, Lorbrena, Xalkori |
| Genmab U.S., INC. | $25.00 | 2023 | Epkinly |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Springworks Therapeutics, INC. | $20.25 | 2024 | Ogsiveo |
| Glaxosmithkline, LLC. | $20.18 | 2024 | Ojjaara |
| Immunocore Limited | $20.00 | 2024 | Kimmtrak |
| Karyopharm Therapeutics INC. | $19.88 | 2024 | Xpovio |
| Adc Therapeutics America, INC. | $19.87 | 2024 | |
| Apellis Pharmaceuticals, INC. | $19.19 | 2023 | Empaveli |
| Eisai INC. | $19.09 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $19.01 | 2024 | Sancuso |
| Alexion Pharmaceuticals, INC. | $17.79 | 2024 | Ultomiris |
| Sun Pharmaceutical Industries INC. | $17.38 | 2023 | Yonsa, Odomzo |
| Blueprint Medicines Corporation | $16.53 | 2023 | Ayvakit |
| Secura Bio, INC. | $15.54 | 2024 | Copiktra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathi Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.